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Abstract
Background: Palonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be
administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been
studied, even though it could have useful clinical applications. In this study, we evaluate the bioavailability of SC
palonosetron.
Patients and Methods: Patients treated with platinum-based chemotherapy were randomized to receive SC or IV
palonosetron, followed by the alternative route in a crossover manner, during the first two cycles of chemotherapy. Blood
samples were collected at baseline and 10, 15, 30, 45, 60, 90 minutes and 2, 3, 4, 6, 8, 12 and 24 h after palonosetron
administration. Urine was collected during 12 hours following palonosetron. We compared pharmacokinetic parameters
including AUC0–24h, t1/2, and Cmax observed with each route of administration by analysis of variance (ANOVA).
Results: From October 2009 to July 2010, 25 evaluable patients were included. AUC0–24h for IV and SC palonosetron were
respectively 14.1 and 12.7 ng6 h/ml (p = 0.160). Bioavalability of SC palonosetron was 118% (95% IC: 69–168). Cmax was
lower with SC than with IV route and was reached 15 minutes following SC administration.
Conclusions: Palonosetron bioavailability was similar when administered by either SC or IV route. This new route of
administration might be specially useful for outpatient management of emesis and for administration of oral chemotherapy.
Trial Registration: ClinicalTrials.gov NCT01046240
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Introduction
Emesis remains one of the most relevant side effects of
chemotherapy. It induces a decrease in health-related quality of
life and it is often underestimated by physicians [1,2]. 5-
hydroxytryptamine-3 (5-HT3) inhibitors are universally recom-
mended as part of standard anti-emetic premedication for
moderate and highly emetogenic chemotherapy agents [3,4].
Palonosetron (Aloxi; Italfarmaco Laboratories,) is a potent and
highly selective 5-HT3 inhibitor with a prolonged half-life
(40 hours), which has up to 30 times higher affinity for the
receptor than first-generation 5-HT3 antagonists. In addition, it
has weak antagonistic action against other 5-HT receptors [5].
The efficacy of palonosetron in the prevention of nausea and
vomiting has been shown in several phase III studies [6–8].
Palonosetron, as the other 5-HT3 antagonists, can be admin-
istered by oral or intravenous (IV) route. However, these routes
are inadequate for patients managed in the outpatient setting that
cannot tolerate oral medication, due to vomiting or other reasons.
Subcutaneous (SC) administration of palonosetron could be an
attractive option for these patients and for those that receive oral
chemotherapy and do not require an intravenous access.
Theoretical advantages of SC route over IV delivery include its
simpler administration, as well as its decreased complications and
costs. In a previous study, we compared the administration of SC
and IV granisetron and we found that both administration routes
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have similar bioavailability [9]. The objective of this study was to
compare the bioavailability of SC and IV palonosetron, in order to
establish the validity of SC administration for cancer patients. We
performed a pharmacokinetic evaluation of SC and IV palonose-
tron, using a randomized crossover design. We hypothesized that
bioavailability of SC palonosetron would not be inferior to that
achieved by IV delivery.
Patients and Methods
Eligible patients had to be candidates to receive platinum-based
chemotherapy. Additional inclusion criteria were: adequate bone
marrow, renal and hepatic function, respectively defined by:
absolute neutrophil count $1500/mm3 and platelets $100000/
mm3; creatinine,1.5 mg/dl; and bilirubin, AST and ALT#2
times x upper limit of normality. Patients must had ECOG
performance status #2. Patients were not eligible in case of
pregnancy or relevant concomitant diseases.
Chemotherapy was the same in both cycles for each patient.
Patients were randomized to receive SC or IV palonosetron
250 mg during the first cycle and to crossover to the alternative
route during the second one. For IV treatment, 250 mg of
palonosetron were injected over 30 seconds. For SC treatment
250 mg of palonosetron were administered subcutaneously in the
abdomen. Patients received 20 mg of intravenous dexamethasone
and further anti-emetic treatment if necessary, although no
additional doses of palonosetron were administered, to avoid
pharmacokinetic interference. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
The main endpoint was bioavailability (F). Even though the
study was not designed to test clinical efficacy, patients evaluated
their emetic symptoms by completing a diary. Toxicity was
assessed using Common Toxicity Criteria for adverse events (CTCAE)
version 3.0. (http://ctep.cancer.gov/protocoldevelopment/electronic
_applications/docs/ctcaev3.pdf).
All patients signed written informed consent before treatment.
The protocol was approved by the Clinical Research Ethics
Committee of Navarra and by the Spanish Agency for Medicines
and Healthcare Products. The trial was registered in Clinical-
Trials.gov (NCT01046240, URL: http://clinicaltrials.gov/ct2/
show/NCT01046240?term = palonosetron+sadaba&rank = 1).
Pharmacokinetic study
Blood samples (5 ml) were obtained at baseline (pre-dose), 10,
15, 30, 45, 60 minutes and 1.5, 2, 3, 4, 6, 8, 12 and 24 hours
following administration of palonosetron. Blood was drawn in
heparin tubes, centrifuged (4uC, 3500 r.p.m., 10 minutes) and
frozen at 220uC until analysis. Urine was collected for 12 hours
after treatment. Palonosetron levels were determined by a
validated high performance liquid chromatography with mass/
mass detection after liquid/liquid extraction of acidified plasma
samples. The quantitation limit was 0.1 ng/ml. Calibration curves
were prepared at a concentration range of 0. 1–100 ng/ml.
Plasma concentrations were analyzed by a laboratory certified in
Good Laboratory Practices.
Pharmacokinetic parameters were calculated by noncomparti-
mental methods. All calculations were carried out using WinNon-
lin Professional Version 5.3 (Scientific Consulting, Inc., Mountain
View, USA). AUC0–12h and AUC0–24h were calculated by the
trapezoidal rule. Maximum concentration (Cmax) and time to
maximum concentration (tmax) were obtained from experimental
data. Half-life (t1/2) and terminal phase rate constant (ke) were
determined by unweighted non-linear regression analysis of the
terminal slope of the log-plasma concentration-time curve.
Statistical analysis
Twenty-five patients were required to have a power of 0.80 in
order to conclude equivalence at the significance level 0.05 in total
bioavailability of SC administration in relation to IV administra-
tion. We compared pharmacokinetic parameters by analysis of
variance (ANOVA) including the factors sequence, period,
formulation and study participant to the log-transformed param-
eters log(AUC) and log(Cmax). We estimated the relative bioavail-
ability and the 90% confidence intervals (CIs) by the residual
variance of the ANOVA [10]. Other pharmacokinetic parameters
were analyzed by paired Student’s t test or Wilcoxon test.
Statistical analysis was performed using SPSS 15.0 and WinNonlin
Pro 5.3. The emetic symptoms were compared by McNemar’s
test. The 95% Cis for proportions were calculated using Epiinfo
6.11.
Results
From October 2009 to July 2010, 25 evaluable patients were
included. Four additional patients were not evaluable because of
anaphylactic shock during administration of paclitaxel (1),
Table 1. Patient characteristics.
N % Mean Range
Patients 25 - - -
Age (years) - - 58 31-74
Sex
Male 18 72
Female 7 28 - -
Weight (kg) - - 77 50.8-121
Height (cm) - - 167.6 153-182
Body mass index (kg/m2) - - 27.2 19.2-38.1
ECOG
0 10 40 - -
1 12 48 - -
2 3 12 - -
Tumours
NSCLC stage IV 12 48 - -
SCLC 2 8 - -
Bladder cancer 5 20 - -
Pelvis kidney cancer 1 4 - -
Tongue cancer 1 4 - -
Nasopharynx cancer 2 8 - -
Testicular cancer 1 4 - -
Cancer of unknown
origin
1 4 - -
Platinum
Cisplatin 21 84 - -
Carboplatin 4 16 - -
Dose of platinum (mg)
Cisplatin - - 131.5 48–165
Carboplatin - - 626.5 450–750
doi:10.1371/journal.pone.0089747.t001
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volunteer decision to leave the study (1), death due to disease
progression (1) and chemotherapy related neutropenia (1). Patient
characteristics are described in table 1. Gender distribution was 18
male (72%) and 7 female (28%). Mean age was 58 years
(SD = 12.4) and mean body mass index 27.2 kg/m2 (SD = 4.7).
Pharmacokinetic assessment
Pharmacokinetic parameters are presented in table 2. Maxi-
mum plasma concentrations were observed right at the end of the
IV infusion and 15 minutes after SC administration. Cmax
obtained after SC route was 15% (95% CI, 11–20%) of that one
achieved by IV administration. Mean palonosetron plasma
concentrations are presented on figures 1 and 2. AUC0–24h and
urinary elimination (20% dose administrated) were similar
between both routes, indicating similar bioavailability with a
relative F of 1.18 (118%). Other pharmacokinetic parameters,
such as t1/2 and ke were not statistically different.
Efficacy and toxicity assessment
From 25 patients evaluable for antiemetic efficacy, 11 (44%)
reported no differences in antiemetic control between both
alternatives, 6 (24%) had less emesis with SC palonosetron and
8 (32%) presented better control with the IV route. These
differences were not statistically significant.
Nine patients (36%) reported constipation, (5 grade 1 and 4
grade 2). Other reported adverse events potentially related with
study drug were headache (2), diarrhoea (2), hiccups (2), dizziness
(1), skin rash (1) and bruise in the injection site (1). All these events
were grade 1 and 2 and none were significantly more frequent
with either administration route.
Discussion
In this study, we have shown that palonosetron presents similar
bioavailability when administered by either SC or IV route,
confirming non-significant differences in AUC and urinary
recovery between both routes. Therefore SC palonosetron seems
a valid alternative to IV administration for control of emesis. This
route could be of particular interest when conventional routes are
difficult or impossible to use, for example, when heavy vomiting
precludes oral intake or when IV administration is not possible in
an outpatient setting. In addition, the SC route might be an
interesting alternative for patients receiving oral chemotherapy
that do not require IV medication.
Guidelines for management of emesis recommend the use of
palonosetron with chemotherapy of moderate and high emetic
potential (level 1, uniform consensus), and with chemotherapy
regimens lasting over one day (level 2A, uniform consensus)
[3,4,11]. We used a 250 mg dose of palonosetron since higher
doses have not shown superior anti-emetic effect [12].
The observed t1/2 for the SC e IV routes were respectively
14.68 hours and 12.71 hours, within the range observed in
Figure 1. Palonosetron mean plasma levels (±SD) following a single 250 mg dose IV or SC (first 24 h, semilogarithmic graph).
doi:10.1371/journal.pone.0089747.g001
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previous studies [13,14] Plasma palonosetron concentrations
declined biexponentially after IV administration, with an initial
rapid distribution phase followed by a slower elimination from the
body. A Cmax value of 5.63 ng/ml (SD = 5.48) has been previously
reported after IV administration of 3 mg/kg (168–270 mg) of
palonosetron over 30 seconds [12]. Considering differences in dose
and sampling time, this is consistent with the Cmax of 11.88
(SD = 7.38) ng/ml that we observed following IV administration.
Absorption after SC administration of palonosetron was slow, and
showed some influence of the absorption phase in the disposition
of the drug. The maximum concentration was achieved 10–
32 min after the dose, with an 85% reduction of Cmax achieved
after IV injection. In a previous study, a 15 minute IV infusion of
250 mg of palonosetron reduced decreased by 40% Cmax as
compared with a 30 second infusion [15]. It is unlikely that the
differences in Cmax observed between both routes can affect
clinical efficacy, because the higher plasma concentrations after IV
injection just lasted a short period of time, inferior to 5 minutes. In
addition, since antiemetics are usually administered 30 to 60
minutes before chemotherapy, this difference is unlikely to affect
clinical efficacy under a prophylactic point of view. Nevertheless, it
could favor the IV route for treatment of established emesis,
although, as previously mentioned, higher doses of palonosetron
have not demonstrated higher clinical efficacy than lower doses.
This trial was not designed to compare the efficacy of both
alternatives, and therefore, no definitive conclusions on this issue
Figure 2. Palonosetron mean plasma levels (±SD) following administration of a single 250 mg dose IV or SC (first two hours).
doi:10.1371/journal.pone.0089747.g002
Table 2. Pharmacokinetic characteristics of subcutaneous
and intravenous palonosetron, compared by Student’s t test
for paired samples and Wilcoxon’s test.
IV SC p
mean (± SD) Mean (± SD)
AUC0-24h (ng6h/ml) 14.1066.73 12.6866.70 0.160
Cmax (ng/ml) 11.8867.38 1.9161.09 ,0.001
tmax (min)
1 1 (1–10) 15 (10–32) ,0.001*
ke (h
21) 0.09560.117 0.07560.061 0.527 *
t1/2 (h) 12.71610.21 14.6869.79 0.527 *
C12h(ng/ml) 0.48760.292 0.45960.289 0.671
C24h(ng/ml) 0.41560.206 0.41460.235 0.365
Ae24h (%) 19.4869.99 22.2468.50 0.660
IV: intravenous. SC: subcutaneous. AUC0–24h: area under the plasma drug
concentration-time curve between 0 to 24 hours. n.s.s: non statistically
significant. Cmax: maximum concentration. tmax: time to maximum
concentration. ke: elimination constant t1/2: half life. C: concentration. Ae:
amount of palonosetron eliminated by urine.
*: Wilcoxon’s test.
1: Median and range.
doi:10.1371/journal.pone.0089747.t002
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can be established based on our results. Yet, 44% of the patients
reported no differences in control of emesis between both routes of
administration, while 24% and 32% reported better control with
SC and IV palonosetron respectively. These results were not
statistically significant, and therefore suggest that SC administra-
tion might have similar antiemetic efficacy than the IV route, but
additional studies will be necessary to confirm such preliminary
observation.
Local toxicity was mild, with only 1 patient presenting a local
reaction, which consisted on a bruise. Systemic toxicity mainly
consisted on grade 1–2 headache and constipation. These adverse
effects have previously been reported with 5-HT3 antagonists,
including palonosetron. While the rate of headache is similar to
what has previously been described [16], the proportion of patients
presenting constipation is somewhat higher [17]. Nevertheless, this
is probably explained by the fact that 4 patients presented previous
constipation.
Conclusion
SC administration of palonosetron has similar bioavailability
than IV delivery. This is the first study that shows that SC
palonosetron might be a valid alternative to IV administration.
This new route of administration might be specially relevant for
outpatient management of emesis in cancer patients and for oral
chemotherapy regimens. Further studies are warranted to confirm
the clinical value of SC palonosetron.
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